Summit Therapeutics Updates Business Address & Phone in 8-K Filing
Ticker: SMMT · Form: 8-K · Filed: Jan 3, 2024 · CIK: 1599298
| Field | Detail |
|---|---|
| Company | Summit Therapeutics Inc. (SMMT) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, compliance
TL;DR
**Summit Therapeutics filed an 8-K for a routine address and phone number update.**
AI Summary
Summit Therapeutics Inc. filed an 8-K on January 3, 2024, to update its corporate information, specifically its business address to 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025, and its telephone number to (650) 460-8308. This filing, under Item 8.01 "Other Events," primarily serves to ensure the company's public records are current. For investors, this administrative update indicates the company is maintaining its compliance and operational transparency, which is a positive sign of good corporate governance.
Why It Matters
This filing is an administrative update, ensuring public records for Summit Therapeutics Inc. are accurate, which is important for transparency and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is purely administrative and does not contain any information that would materially impact the company's operations or financial standing.
Analyst Insight
A smart investor would note this as a routine administrative update, confirming the company's compliance with reporting requirements, but it provides no new information to alter investment decisions.
Key Players & Entities
- Summit Therapeutics Inc. (company) — the registrant filing the 8-K
- January 3, 2024 (date) — date of earliest event reported and filing date
- 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025 (address) — new principal executive offices address
- (650) 460-8308 (phone_number) — new registrant's telephone number
- 001-36866 (string) — Commission File Number
- SMMT (string) — Trading Symbol for Common stock
- The Nasdaq Stock Market LLC (company) — Exchange where Common stock is registered
FAQ
What is the primary purpose of Summit Therapeutics Inc.'s 8-K filing on January 3, 2024?
The primary purpose of Summit Therapeutics Inc.'s 8-K filing on January 3, 2024, is to report an "Other Event" under Item 8.01, specifically updating its principal executive offices address to 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025, and its telephone number to (650) 460-8308.
What is the new business address for Summit Therapeutics Inc. as reported in this filing?
As reported in this filing, the new business address for Summit Therapeutics Inc. is 2882 Sand Hill Road, Suite 106, Menlo Park, CA 94025.
What is the new telephone number for Summit Therapeutics Inc. according to the 8-K?
According to the 8-K, the new telephone number for Summit Therapeutics Inc. is (650) 460-8308.
Under which item of Form 8-K was this information reported?
This information was reported under Item 8.01, titled "Other Events," of Form 8-K.
What is the trading symbol and the exchange where Summit Therapeutics Inc.'s common stock is registered?
Summit Therapeutics Inc.'s common stock, with a $0.01 par value per share, has the trading symbol SMMT and is registered on The Nasdaq Stock Market LLC.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-01-03 16:06:38
Key Financial Figures
- $0.01 — ange on Which Registered Common stock, $0.01 par value per share SMMT The Nasdaq Sto
Filing Documents
- smmt-20240103.htm (8-K) — 29KB
- a2024_prx0103xjpmannounc.htm (EX-99.1) — 8KB
- a2024_prx0103xjpmannounc001.jpg (GRAPHIC) — 240KB
- a2024_prx0103xjpmannounc002.jpg (GRAPHIC) — 246KB
- 0001599298-24-000004.txt ( ) — 832KB
- smmt-20240103.xsd (EX-101.SCH) — 2KB
- smmt-20240103_lab.xml (EX-101.LAB) — 23KB
- smmt-20240103_pre.xml (EX-101.PRE) — 12KB
- smmt-20240103_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 3, 2024, Summit Therapeutics Inc. (the "Company") issued a press release announcing that the Company will participate in and present at the 42nd Annual J.P. Morgan Healthcare Conference. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated January 03, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. SUMMIT THERAPEUTICS INC. Date: January 3, 2024 By: /s/ Ankur Dhingra Chief Financial Officer (Principal Financial Officer)